TheraRadar
← Back
Data updated: Jun 28, 2026

CADILA PHARMS LTD

Generics

CADILA PHARMS LTD is a generic drug manufacturer focused on Cardiovascular, Metabolic, Oncology.

2013
Since
29
Drugs
-
Trials
0
New Drugs (2yr)

CADILA PHARMS LTD's Key Drugs

CADILA PHARMS LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CADILA PHARMS LTD's Recent FDA Approvals

New NDA/BLA approvals for CADILA PHARMS LTD over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CADILA PHARMS LTD's Therapeutic Areas

CADILA PHARMS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 44%
4 drugs
Metabolic 22%
2 drugs
Oncology 11%
1 drugs
Dermatology 11%
1 drugs
Neurology 11%
1 drugs

CADILA PHARMS LTD's Top Competitors

CADILA PHARMS LTD's closest competitors by therapeutic-area and drug-target overlap include Baxter, Eli Lilly, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

CADILA PHARMS LTD Pipeline Snapshot

Active clinical trials for CADILA PHARMS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling